Pilot Study Evaluating the Safety and Efficacy of a New Hard-on-Hard Total Hip Replacement System

April 18, 2023 updated by: Smith & Nephew, Inc.

A Consecutive Series Pilot Study Evaluating the Safety and Effectiveness of a New Hard-on-Hard Total Hip Replacement System in Patients With Non-inflammatory Arthritis With a Standard THA Metal Ion Control Group

The purpose of this study is to assess the early and long term safety and efficacy of the hard-on-hard total hip replacement system (R3 ODH-ODH utilization) in patients with non-inflammatory arthritis.

Study Overview

Status

Active, not recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

26

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Durban, South Africa, 4001
        • Entabeni Hospital
      • Pretoria, South Africa, 0002
        • Zuid Afrikaans Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • At least 21 years old
  • Skeletally mature
  • Requires primary, unilateral total hip arthroplasty due to degenerative join disease
  • Preoperative Harris Hip Score of less than or equal to 70
  • Meets an acceptable preoperative medical clearance and is free or treated for conditions that would pose excessive operative risk
  • Given consent to participate in the study
  • Able to understand the purpose of the study, his/her role, and is available for follow-up

    10 year extension:

    • Subject has completed the 2 year primary study
    • Subject has signed an Independent Ethics Committee (IEC) approved Informed Consent Form agreeing to participate in the extension study after the nature, scope and possible consequences of the study have been explained in an understandable form
    • Subject is able to fully understand the purpose of the study, his/her role as a participant in the study, and plans to be available through ten years post-operative follow-up

Exclusion Criteria:

  • Diagnosis with high risk of Total Hip Arthroplasty (THA) failure
  • Requires bilateral THA
  • Requires revision of a prior hip replacement
  • Active infection or sepsis
  • History of local hip infection
  • Known metastatic or neoplastic disease
  • Conditions that may interfere with THA survival or outcomes
  • Need for structural bone grafts to support the implant
  • Contralateral lower extremity condition
  • Has other joint replacements or plans for other joint replacements within 2 years
  • Systemic steroid therapy within 3 months prior to surgery
  • Life expectancy less than 2 years
  • Intra-articular therapy within 6 months of enrollment
  • Female of child-bearing age not using contraception
  • Inadequate bone stock to support the device
  • Moderate to severe renal insufficiency
  • Emotional or neurological condition that would pre-empt ability or willingness to participate in the study
  • BMI >40
  • Above the knee amputation of the contralateral or ipsilateral leg
  • Known allergies to the components of the devices
  • Entered into another investigational study
  • Is a prisoner

    10 year extension:

    • In the opinion of the surgeon, the subject's health, safety or well-being may be compromised or harmed by continuation in the extension phase or participation may not be in the subject's best interests.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control Total Hip Replacement Device

Total Hip replacement surgery using control device consisting of a hard-on-soft bearing or a ceramic-on-ceramic bearing which includes:

  • R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem
  • OXINIUM heads on polyethylene liners or
  • Ceramic heads on ceramic liners (all uncemented components)
Other Names:
  • Total Hip Replacement
  • Total Hip Arthroplasty
  • THA
  • THR
Experimental: Investigational Hard-on-Hard Total Hip Replacement Device

Total Hip replacement surgery using an experimental device consisting of a hard-on-hard bearing which includes:

  • R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem
  • R3 ODH acetabular cup liners (sizes 38/50, 40/52, 42/54 and 44/56 mm)
  • R3 ODH femoral heads (sizes 38, 40, 42 and 44 mm)
  • Taper sleeves Ti -6AL-4V (sizes -4, +0, +4, and +8)
Other Names:
  • Total Hip Replacement
  • Total Hip Arthroplasty
  • THA
  • THR

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Revision Rate
Time Frame: Up to 10 Years
Reoperations that led to removal or replacement of any of the acetabular or femoral components.
Up to 10 Years
Adverse Events
Time Frame: Up to 10 Years
Up to 10 Years
Metal Ion Concentration in Whole Blood
Time Frame: Up to 10 years
Up to 10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Harris Hip score
Time Frame: Up to 10 years
Up to 10 years
Hip Disability and Osteoarthritis Outcome Scores (HOOS)
Time Frame: Up to 10 years
Up to 10 years
Radiographic measures
Time Frame: Up to 10 years
Assessment of bone loss, radiolucencies, subsidence, and heterotopic ossification
Up to 10 years
Health economic outcomes-Surgical blood loss
Time Frame: Intra-operative
Measured in ml blood
Intra-operative
Health economic outcomes -Length of hospital stay
Time Frame: Hospital admission to discharge
Measure of days spent in hospital
Hospital admission to discharge
Health economic outcomes-Operative time
Time Frame: Intra-operative
Operative time - first incision into skin to time when last suture is applied
Intra-operative
Health economic outcomes - Re-hospitalisations
Time Frame: Up to 10 years
Re-hospitalisations-number of re-admissions to hospital
Up to 10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 4, 2011

Primary Completion (Actual)

June 1, 2014

Study Completion (Anticipated)

September 1, 2023

Study Registration Dates

First Submitted

May 13, 2014

First Submitted That Met QC Criteria

May 30, 2014

First Posted (Estimate)

June 3, 2014

Study Record Updates

Last Update Posted (Actual)

April 19, 2023

Last Update Submitted That Met QC Criteria

April 18, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 2011-ODHH166

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Arthritis, Degenerative

Clinical Trials on ODH Hip System

3
Subscribe